U.S. Department of Health & Human Services
National Institutes of Health
NCATS
This repository is under review for potential modification in compliance with Administration directives.
Dismiss
Return Home
Inxight
Drugs
Search Substances
Home
Browse Drugs
US Approved Drugs
Marketed Drugs
Investigational Drugs
All Substances
Search
Structure Search
Sequence Search
Downloads
About
Search Substances
Cosibelimab
PNW7GBB44P
US Approved Rx (2024)
First approved in 2024
General
Names
9
Classification
2
Identifiers
6
Subunits
4
Related Substances
1
Cosibelimab
PNW7GBB44P
US Approved Rx (2024)
First approved in 2024
General
Approval Year
2024
711
Names
9
Show
5
20
100
All
entries
Name
Type
Language
Name
Type
Language
CK-301
Preferred Name
English
Cosibelimab
Official Name
English
ANTI-PD-L1 MONOCLONAL ANTIBODY CK-301
Common Name
English
cosibelimab [INN]
Common Name
English
TG-1501
Code
English
Showing 1 to 5 of 9 entries
Previous
1
2
Next
Classification
2
Show
5
20
100
All
entries
Classification Tree
Code System
Code
Classification Tree
Code System
Code
Monoclonal Antibody
Pharmacologic Substance
[C1909]
Biological Agent
[C307]
Monoclonal Antibody
[C20401]
Anti-PD-L1 Monoclonal Antibody
NCI_THESAURUS
C128057
Antineoplastic Biological Agent
Pharmacologic Substance
[C1909]
Biological Agent
[C307]
Antineoplastic Biological Agent
[C129821]
Antineoplastic Antibody
NCI_THESAURUS
C129822
Showing 1 to 2 of 2 entries
Previous
1
Next
Identifiers
6
Show
5
20
100
All
entries
Code System
Code
Type
Description
Code System
Code
Type
Description
SMS_ID
300000009702
PRIMARY
CAS
2216751-26-5
PRIMARY
INN
11107
PRIMARY
FDA UNII
PNW7GBB44P
PRIMARY
USAN
HI-183
PRIMARY
Showing 1 to 5 of 6 entries
Previous
1
2
Next
Subunits
4
Related Substances
1
ACTIVE MOIETY
PNW7GBB44P
Cosibelimab
